Instil Bio, Inc. and ImmuneOnco Biopharmaceuticals provided updates on the clinical development of AXN-2510/IMM2510, their PD-L1xVEGF bispecific antibody. The Phase 2 trial in combination with chemotherapy for first-line non-small cell lung cancer (NSCLC) in China is on track to complete enrollment in the third quarter of 2025. Initial results from this trial are anticipated in the second half of 2025.
ImmuneOnco anticipates starting a Phase 3 trial of AXN-2510 in combination with chemotherapy in first-line NSCLC in China in mid-2026, subject to regulatory discussions. This indicates a clear path forward for the program in China.
For U.S. clinical development, Instil announced a revised strategy. The previously planned U.S. trial will be replaced by a monotherapy dose optimization Phase 1b/2 trial of AXN-2510 in relapsed/refractory solid tumors. This new trial is intended to bridge the doses to the ongoing China trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.